PMID- 10329429
OWN - NLM
STAT- MEDLINE
DCOM- 19990624
LR  - 20101118
IS  - 0006-291X (Print)
IS  - 0006-291X (Linking)
VI  - 258
IP  - 3
DP  - 1999 May 19
TI  - Molecular cloning and characterization of a surface antigen preferentially
      overexpressed on multiple myeloma cells.
PG  - 583-91
AB  - HM1.24 antigen has been identified as a surface molecule preferentially expressed
      on terminally differentiated B cells, and its overexpression is observed in
      multiple myeloma cells. The HM1.24 antigen is, therefore, expected as a most
      potent target molecule for antibody-based immunotherapy for multiple myeloma.
      Here, we have identified the cDNA for human HM1.24 antigen and also analyzed its 
      gene structure including the promoter region. The HM1.24 antigen is a type II
      membrane glycoprotein, which has been reported as a bone marrow stromal cell
      surface antigen BST2, and may exist as a homodimer on myeloma cell surface.
      Although a reason for the overexpression in myeloma cells is not understood, very
      interestingly, the promoter region of the HM1.24 gene has a tandem repeat of
      three cis elements for a transcription factor, STAT3, which mediates
      interleukin-6 (IL-6) response gene expression. Since IL-6 is a differentiation
      factor for B cells, and known as a paracrine/autocrine growth factor for multiple
      myeloma cells, the expression of HM1.24 antigen may be regulated by the
      activation of STAT3. Importantly, a humanized anti-HM1.24 antibody effectively
      lysed the CHO transformants which expressed HM1.24 antigen as high as human
      multiple myeloma cells, but not the cells with lower antigen expression. This
      evaluation shows that ADCC heavily depends on the expression level of target
      antigens and, therefore, the immunotherapy targeting the HM1.24 antigen should
      have a promising potential in clinical use.
CI  - Copyright 1999 Academic Press.
FAU - Ohtomo, T
AU  - Ohtomo T
AD  - Chugai Pharmaceutical Co., Ltd., Fuji-Gotemba Research Labs., 1-135 Komakado,
      Gotemba-shi, Shizuoka, 412-8513, Japan.
FAU - Sugamata, Y
AU  - Sugamata Y
FAU - Ozaki, Y
AU  - Ozaki Y
FAU - Ono, K
AU  - Ono K
FAU - Yoshimura, Y
AU  - Yoshimura Y
FAU - Kawai, S
AU  - Kawai S
FAU - Koishihara, Y
AU  - Koishihara Y
FAU - Ozaki, S
AU  - Ozaki S
FAU - Kosaka, M
AU  - Kosaka M
FAU - Hirano, T
AU  - Hirano T
FAU - Tsuchiya, M
AU  - Tsuchiya M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Surface)
RN  - 0 (BST2 protein, human)
RN  - 0 (DNA, Complementary)
RN  - 0 (GPI-Linked Proteins)
RN  - 0 (Membrane Glycoproteins)
SB  - IM
MH  - Amino Acid Sequence
MH  - Animals
MH  - Antibody-Dependent Cell Cytotoxicity
MH  - Antigens, CD
MH  - Antigens, Surface/chemistry/*genetics/immunology
MH  - Base Sequence
MH  - CHO Cells
MH  - Cloning, Molecular
MH  - Cricetinae
MH  - DNA, Complementary
MH  - GPI-Linked Proteins
MH  - Humans
MH  - Macaca mulatta
MH  - Membrane Glycoproteins/chemistry/*genetics/immunology
MH  - Mice
MH  - Molecular Sequence Data
MH  - Multiple Myeloma/*immunology/pathology
MH  - Promoter Regions, Genetic
MH  - Tumor Cells, Cultured
EDAT- 1999/05/18 00:00
MHDA- 1999/05/18 00:01
CRDT- 1999/05/18 00:00
PHST- 1999/05/18 00:00 [pubmed]
PHST- 1999/05/18 00:01 [medline]
PHST- 1999/05/18 00:00 [entrez]
AID - S0006-291X(99)90683-6 [pii]
AID - 10.1006/bbrc.1999.0683 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 1999 May 19;258(3):583-91. doi:
      10.1006/bbrc.1999.0683.